Tan S, Kasperbauer S. Nontuberculous Mycobacteria. Semi Respiratory Crit Care Med. 2021;42:567–86. https://doi.org/10.1055/s-0041-1730997.

Article  Google Scholar 

Lopez-Luis BA, Sifuentes-Osornio J, Pérez-Gutiérrez MT, Chávez-Mazari B, Bobadilla-Del-Valle M, Ponce-de-León A. Nontuberculous mycobacterial infection in a tertiary care center in Mexico, 2001–2017. Braz J Infect Dis. 2020;24(3):213–220. https://doi.org/10.1016/j.bjid.2020.04.012. Epub 2020 May 16. PMID: 32428442.

López-Roa P, Aznar E, Cacho J, Cogollos-Agruña R, Domingo D, García-Arata MI, Millán R, Páez M, Perez-Cecilia E, Ruiz-Serrano MJ, Simón M, Tato M, Toro C, Valverde JF, Esteban J. Epidemiology of non-tuberculous mycobacteria isolated from clinical specimens in Madrid, Spain, from 2013 to 2017. Eur J Clin Microbiol Infect Dis. 2020;39:1089–94. https://doi.org/10.1007/s10096-020-03826-7. (Epub 2020 Jan 24 PMID: 31980987).

Article  CAS  PubMed  Google Scholar 

Ji S, Xu W, Sun J, Shi Y, Pan X. Retrospective analysis of patients with non-tuberculous mycobacteria from a primary hospital in Southeast China. Sci Rep. 2020;10:1060. https://doi.org/10.1038/s41598-020-58105-4.PMID:31974461;PMCID:PMC6978455.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Matsumoto Y, Kinjo T, Motooka D, Nabeya D, Jung N, Uechi K, Horii T, Iida T, Fujita J, Nakamura S. Comprehensive subspecies identification of 175 nontuberculous mycobacteria species based on 7547 genomic profiles. Emerg Microbes Infect. 2019;8:1043–53. https://doi.org/10.1080/22221751.2019.1637702.PMID:31287781;PMCID:PMC6691804.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Daley CL, Iaccarino JM, Lange C, Cambau E, Wallace RJ Jr, Andrejak C, Böttger EC, Brozek J, Griffith DE, Guglielmetti L, Huitt GA, Knight SL, Leitman P, Marras TK, Olivier KN, Santin M, Stout JE, Tortoli E, van Ingen J, Wagner D, Winthrop KL. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Eur Respir J. 2020;56:2000535. https://doi.org/10.1183/13993003.00535-2020.PMID:32636299;PMCID:PMC8375621.

Article  PubMed  PubMed Central  Google Scholar 

Lange C, Böttger EC, Cambau E, Griffith DE, Guglielmetti L, van Ingen J, Knight SL, Marras TK., Olivier KN, Santin M, Stout JE, Tortoli E, Wagner D, Winthrop K, Daley CL, expert panel group for management recommendations in non-tuberculous mycobacterial pulmonary diseases (2022). Consensus management recommendations for less common non-tuberculous mycobacterial pulmonary diseases. The Lancet. Infectious diseases, 22(7), e178–e190. https://doi.org/10.1016/S1473-3099(21)00586-7

Pfaeffle HOI, Alameer RM, Marshall MH, Houpt ER, Albon DP, Heysell SK. Clofazimine for treatment of multidrug-resistant non-tuberculous mycobacteria. Pulm Pharmacol Ther. 2021;70: 102058. https://doi.org/10.1016/j.pupt.2021.102058.

Article  CAS  PubMed  Google Scholar 

McGuffin SA, Pottinger PS, Harnisch JP (2017) Clofazimine in nontuberculous mycobacterial infections: a growing niche. Open forum infectious diseases, 4(3): ofx147. https://doi.org/10.1093/ofid/ofx147

Kim DH, Kim BG, Kim SY, Huh HJ, Lee NY, Koh WJ, Kim H, Kwon OJ, Jhun BW. In vitro activity and clinical outcomes of clofazimine for nontuberculous mycobacteria pulmonary disease. J Clin Med. 2021;10:4581. https://doi.org/10.3390/jcm10194581.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang B, Jhun BW, Moon SM et al. A clofazimine-containing regimen for the treatment of Mycobacterium abscessus lung disease. Antimicrob Agents Chemother 2017; 61:pii: e02052–16.

Nasiri MJ, Calcagno T, Hosseini SS, Hematian A, Nojookambari NY, Karimi-Yazdi M, Mirsaeidi M. Role of clofazimine in treatment of Mycobacterium avium Complex. Front Med. 2021;8: 638306. https://doi.org/10.3389/fmed.2021.638306.

Article  Google Scholar 

Riccardi N, Giacomelli A, Canetti D, Comelli A, Intini E, Gaiera G, Diaw MM, Udwadia Z, Besozzi G, Codecasa L, Biagio AD. Clofazimine: an old drug for never-ending diseases. Future Microbiol. 2020;15:557–66. https://doi.org/10.2217/fmb-2019-0231.

Article  CAS  PubMed  Google Scholar 

Aliberti S, Codecasa LR, Gori A, Sotgiu G, Spotti M, Di Biagio A, Calcagno A, Nardini S, Assael BM, Tortoli E, Besozzi G, Ferrarese M, Matteelli A, Girardi E, De Lorenzo S, Seia M, Gramegna A, Del Prato B, Terranova L, Oriano M, Sverzellati N, Mirsaeidi M, Chalmers JD, Haworth CS, Loebinger MR, Aksamit T, Winthrop K, Ringshausen FC, Previdi G, Blasi F; IRENE Network. The Italian registry of pulmonary non-tuberculous mycobacteria - IRENE: the study protocol. Multidiscip Respir Med. 2018 Aug 9;13(Suppl 1):33. https://doi.org/10.1186/s40248-018-0141-8

Diel R, Jacob J, Lampenius N, et al. Burden of non-tuberculous mycobacterial pulmonary disease in Germany. Eur Respir J. 2017;49(4).

Strollo SE, Adjemian J, Adjemian MK, Prevots DR. The burden of pulmonary nontuberculous mycobacterial disease in the United States. Ann Am Thorac Soc. 2015;12:1458–64.

Article  PubMed  PubMed Central  Google Scholar 

Ballarino GJ, Olivier KN, Claypool RJ, Holland SM, Prevots DR. Pulmonary nontuberculous mycobacterial infections: antibiotic treatment and associated costs. Respir Med. 2009;103:1448–55.

Article  PubMed  PubMed Central  Google Scholar 

Adjemian J, Prevots DR, Gallagher J, Heap K, Gupta R, Griffith D. Lack of adherence to evidence-based treatment guidelines for nontuberculous mycobacterial lung disease. Ann Am Thorac Soc. 2014;11:9–16. https://doi.org/10.1513/AnnalsATS.201304-085OC.

Article  PubMed  PubMed Central  Google Scholar 

Ricotta EE, Olivier KN, Lai YL, Prevots DR, Adjemian J. Hospital-based antibiotic use in patients with Mycobacterium avium complex. ERJ Open Res. 2018;4:00109–2018. https://doi.org/10.1183/23120541.00109-2018.

Article  PubMed  PubMed Central  Google Scholar 

Suska K, Amati F, Sotgiu G, Gramegna A, Mantero M, Ori M, Ferrarese M, Codecasa LR, Stainer A, Blasi F, Aliberti S. Nontuberculous mycobacteria infection and pulmonary disease in bronchiectasis. ERJ Open Res. 2022;8:00060–2022. https://doi.org/10.1183/23120541.00060-2022.

Article  PubMed  PubMed Central  Google Scholar 

Rindi L, Garzelli C. Increase in non-tuberculous mycobacteria isolated from humans in Tuscany, Italy, from 2004 to 2014. BMC Infect Dis. 2016;16:44. https://doi.org/10.1186/s12879-016-1380-y.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Prato BD, Altieri AM, Carlucci B, Mori PA, Parrella R, Stainer A, Giacomi F, Pesci A, Faverio P, Gruppo di Studio AIPO “Patologie Infettive Respiratorie e Tubercolosi” (2018). Non-tuberculous mycobacterial pulmonary disease: an Italian National survey. Sarcoidosis, Vasculitis, and Diffuse Lung Diseases, 35(1): 21–25. https://doi.org/10.36141/svdld.v35i1.6979

Stefano Aliberti, Maura Spotti, Giovanni Sotgiu, Maurizio Ferrarese, Paola Francesca Castellotti, Andrea Gramegna, Marina Tadolini, Jessica Mencarini, Gina Gualano, Stefania Cerri, Giuliano Montemurro, Giulia Gardini, Andrea Calcagno, Federico Dente, Michele Trezzi, Paola Faverio, Mario Malerba, Giulia Cucchetto, Enrico Tortoli, Mehdi Mirsaeidi, Antonella Previdi, Andrea Gori, Luigi Ruffo Codecasa, Francesco Blasi. A First Look at the Italian Registry on Pulmonary Non-Tuberculous Mycobacteria (NTM) -IRENE. European Respiratory Journal Sep 2020, 56 (suppl 64) 4344; https://doi.org/10.1183/13993003.congress-2020.4344

World Health Organization Model List of Essential Medicines—22nd List, 2021. Geneva: World Health Organization; 2021 (WHO/MHP/HPS/EML/2021.02). Licence: CC BY-NC-SA 3.0 IGO.

Kim BG, Kim H, Kwon OJ, Huh HJ, Lee NY, Baek SY, Sohn I, Jhun BW. Outcomes of inhaled amikacin and clofazimine-containing regimens for treatment of refractory mycobacterium avium complex pulmonary disease. J Clin Med. 2020;9:2968. https://doi.org/10.3390/jcm9092968.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nasiri MJ, Ebrahimi G, Arefzadeh S, Zamani S, Nikpor Z, Mirsaeidi M. Antibiotic therapy success rate in pulmonary Mycobacterium avium complex: a systematic review and meta-analysis. Expert Rev Anti Infect Ther. 2020;18:263–73. https://doi.org/10.1080/14787210.2020.1720650. (Epub 2020 Jan 27 PMID: 31986933).

Article  CAS  PubMed  Google Scholar 

Jeong BH, Jeon K, Park HY, Moon SM, Kim SY, Lee SY, Shin SJ, Daley CL, Koh WJ. Peak plasma concentration of azithromycin and treatment responses in mycobacterium avium complex lung disease. Antimicrob Agents Chemother. 2016;60:6076–83. https://doi.org/10.1128/AAC.00770-16.PMID:27480854;PMCID:PMC5038230.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ruth MM, Sangen JJN, Remmers K, Pennings LJ, Svensson E, Aarnoutse RE, Zweijpfenning SMH, Hoefsloot W, Kuipers S, Magis-Escurra C, Wertheim HFL, van Ingen J. A bedaquiline/clofazimine combination regimen might add activity to the treatment of clinically relevant non-tuberculous mycobacteria. J Antimicrob Chemother. 2019;74:935–43. https://doi.org/10.1093/jac/dky526.

Article  CAS  PubMed  Google Scholar 

Ammerman NC, Swanson RV, Tapley A, Moodley C, Ngcobo B, Adamson J, Dorasamy A, Moodley S, Mgaga Z, Bester LA, Singh SD, Almeida DV, Grosset JH. Clofazimine has delayed antimicrobial activity against Mycobacterium tuberculosis both in vitro and in vivo. J Antimicrob Chemother. 2017;72:455–61. https://doi.org/10.1093/jac/dkw417. (Epub 2016 Oct 25 PMID: 27798204).

Article  CAS  PubMed  Google Scholar 

Padayatchi N, Gopal M, Naidoo R, Werner L, Naidoo K, Master I, O'Donnell MR. Clofazimine in the treatment of extensively drug-resistant tuberculosis with HIV coinfection in South Africa: a retrospective cohort study. J Antimicrob Chemother. 2014 Nov;69(11):3103–7. https://doi.org/10.1093/jac/dku235. Epub 2014 Jun 30. PMID: 24986495; PMCID: PMC4195472.

Mitnick CD, Shin SS, Seung KJ, Rich ML, Atwood SS, Furin JJ, Fitzmaurice GM, Alcantara Viru FA, Appleton SC, Bayona JN, Bonilla CA, Chalco K, Choi S, Franke MF, Fraser HS, Guerra D, Hurtado RM, Jazayeri D, Joseph K, Llaro K, Mestanza L, Mukherjee JS, Muñoz M, Palacios E, Sanchez E, Sloutsky A, Becerra MC. Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med. 2008;359:563–74. https://doi.org/10.1056/NEJMoa0800106.PMID:18687637;PMCID:PMC2673722.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Prideaux B, Via LE, Zimmerman MD, Eum S, Sarathy J, O'Brien P, Chen C, Kaya F, Weiner DM, Chen PY, Song T, Lee M, Shim TS, Cho JS, Kim W, Cho SN, Olivier KN, Barry CE 3rd, Dartois V. The association between sterilizing activity and drug distribution into tuberculosis lesions. Nat Med. 2015 Oct;21(10):1223–7. https://doi.org/10.1038/nm.3937. Epub 2015 Sep 7. PMID: 26343800; PMCID: PMC4598290.

Faouzi M, Starkus J, Penner R. State-dependent blocking mechanism of Kv 1.3 channels by the antimycobacterial drug clofazimine. Br J Pharmacol. 2015 Nov;172(21):5161–73. https://doi.org/10.1111/bph.13283. Epub 2015 Oct 9. PMID: 26276903; PMCID: PMC4687807.

Strydom N, Gupta SV, Fox WS, Via LE, Bang H, Lee M, Eum S, Shim T, Barry CE 3rd, Zimmerman M, Dartois V, Savic RM. Tuberculosis drugs’ distribution and emergence of resistance in patient’s lung lesions: a mechanistic model and tool for regimen and dose optimization. PLoS Med. 2019;16: e1002773. https://doi.org/10.1371/journal.pmed.1002773.PMID:30939136;PMCID:PMC6445413.